Exclusion Criteria:~* Any new medical contraindication or clinically significant abnormality on physical,
neurological, laboratory, vital signs or ECG examination (eg, atrial fibrillation) that precludes continued or
initiation of treatment with bapineuzumab or participation in the study~* Screening visit brain MRI scan (MRI
from Study 301 or 302 Visit 14/Week 71) indicative of any significant abnormality not approved by the medical
monitor prior to enrollment~* Current use of experimental medications for AD (other than bapineuzumab) and all
other experimental medications, herbal preparations containing Ginko biloba, and anticoagulants (except the use
of aspirin 325mg/day or less, Plavix, and Persantine but not for stroke)
